SG11202100240RA - A xinafoate salt of a jak inhibiting compound - Google Patents

A xinafoate salt of a jak inhibiting compound

Info

Publication number
SG11202100240RA
SG11202100240RA SG11202100240RA SG11202100240RA SG11202100240RA SG 11202100240R A SG11202100240R A SG 11202100240RA SG 11202100240R A SG11202100240R A SG 11202100240RA SG 11202100240R A SG11202100240R A SG 11202100240RA SG 11202100240R A SG11202100240R A SG 11202100240RA
Authority
SG
Singapore
Prior art keywords
inhibiting compound
xinafoate salt
jak
jak inhibiting
xinafoate
Prior art date
Application number
SG11202100240RA
Other languages
English (en)
Inventor
Anna Pettersen
James Mccabe
Carl-Johan Aurell
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11202100240RA publication Critical patent/SG11202100240RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
SG11202100240RA 2018-07-18 2019-07-17 A xinafoate salt of a jak inhibiting compound SG11202100240RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862699955P 2018-07-18 2018-07-18
US201962866013P 2019-06-25 2019-06-25
PCT/EP2019/069252 WO2020016302A1 (en) 2018-07-18 2019-07-17 A xinafoate salt of a jak inhibiting compound

Publications (1)

Publication Number Publication Date
SG11202100240RA true SG11202100240RA (en) 2021-02-25

Family

ID=67396927

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100240RA SG11202100240RA (en) 2018-07-18 2019-07-17 A xinafoate salt of a jak inhibiting compound

Country Status (13)

Country Link
US (1) US11149029B2 (ja)
EP (1) EP3823964A1 (ja)
JP (2) JP7422732B2 (ja)
KR (1) KR20210033474A (ja)
CN (1) CN112424187A (ja)
AU (1) AU2019304014B2 (ja)
BR (1) BR112021000467A2 (ja)
CA (1) CA3105585A1 (ja)
IL (1) IL280025A (ja)
MA (1) MA53162A (ja)
MX (1) MX2021000611A (ja)
SG (1) SG11202100240RA (ja)
WO (1) WO2020016302A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2697495C (en) 2007-09-05 2013-02-05 Pfizer Limited Xinafoate salt of n4-[(2,2-difluoro-4h-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine
BR112013006016A2 (pt) * 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
CN105658646B (zh) * 2013-11-01 2018-11-27 诺华股份有限公司 作为激酶抑制剂的氨基杂芳基苯甲酰胺
PT3189045T (pt) 2014-08-11 2022-03-17 Sun Pharmaceutical Ind Ltd Novos sais de nilotinib e polimorfos do mesmo
MX2018003590A (es) * 2015-09-25 2018-11-29 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos y metodos para la inhibicion de jak.
KR102585048B1 (ko) * 2017-01-17 2023-10-05 아스트라제네카 아베 Jak1 선택적 억제제
CN106831538B (zh) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 托法替尼中间体的制备方法

Also Published As

Publication number Publication date
MX2021000611A (es) 2021-04-13
JP2024001109A (ja) 2024-01-09
US20200062737A1 (en) 2020-02-27
KR20210033474A (ko) 2021-03-26
IL280025A (en) 2021-03-01
MA53162A (fr) 2021-05-26
WO2020016302A8 (en) 2020-11-12
WO2020016302A1 (en) 2020-01-23
US11149029B2 (en) 2021-10-19
BR112021000467A2 (pt) 2021-04-06
AU2019304014B2 (en) 2022-08-18
CN112424187A (zh) 2021-02-26
JP7422732B2 (ja) 2024-01-26
CA3105585A1 (en) 2020-01-23
JP2021530526A (ja) 2021-11-11
EP3823964A1 (en) 2021-05-26
AU2019304014A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
IL281518A (en) A process for producing a compound to inhibit the activity of SHP2
EP3619208C0 (en) CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND
ZA201906817B (en) Methods of treatment using a jak inhibitor compound
SI3601283T1 (sl) Kondenzirana imidazo-piperidinska spojina inhibitorja JAK
MA43318A (fr) Nouveau composé de biphényle ou un sel de celui-ci
SG11202103042XA (en) 2-azabicyclo hexane compound as jak inhibitor
EP4067343A4 (en) NOVEL PHENOLIC COMPOUND OR SALT THEREOF
IL269626A (en) Crystalline salt forms of BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2
IL290692A (en) Salt
ZA201903885B (en) Polymorphs of herbicidal sulfonamides
IL280025A (en) JAK xinapoate salt inhibitory compound
FI3891156T3 (fi) Mcl-1-inhibiittorin uusia kiteisiä muotoja, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
PL3717461T3 (pl) Nowy związek izoksazolowy lub jego sól
HK1246786A1 (zh) 吡咯並吡啶化合物的結晶形式
IL276195A (en) Salt forms of an organic compound
IL278054A (en) The crystalline forms of a compound
IL277578A (en) New salt forms of URAT-1 inhibitors
GB201804905D0 (en) Cataltic synthesis of biarylic compounds
GB201809458D0 (en) Salt form
GB201809460D0 (en) Salt form
EP3315493A4 (en) PHENYLAMINOPYRIMIDINE COMPOUND OR POLYMORPH THEREOF
IL284564A (en) Polymorphic forms of a modified quinoline-type bridged piperidine compound
GB201910664D0 (en) Novel forms of compound
ZA201707682B (en) Polymorphs of a pges-1 inhibiting triazolone compound
GB201910665D0 (en) Novel form of compounds